Literature DB >> 6214842

T cells in monoclonal gammopathies.

H Mellstedt, G Holm, D Pettersson, M Björkholm, B Johansson, C Lindemalm, D Peest, A Ahre.   

Abstract

Subpopulations of human T lymphocytes were analysed by monoclonal antibodies (OKT3, OKT4, OKT8) in healthy controls and in patients with multiple myeloma (MM), Waldenström's macroglobulinemia (WM) and benign monoclonal gammopathy (BMG). Lymphocytes forming rosettes with SRBC correlated well with T cells staining in indirect immunofluorescence by OKT3 monoclonal antibodies. The relative and absolute numbers of OKT4+ T cells were significantly lower in patients than in controls. Though, the percentage of OKT8+ T cells was increased in patients, the total OKT8+ cell counts were normal in all patient groups. The ratio between OKT4+ and OKT8+ lymphocytes was low in the groups of treated MM and of WM patients compared to controls (P less than 0.001). Moreover, the ratio was lower than the normal range in 27% of BMG and 38% of untreated MM patients. The imbalance between OKT4+ and OKT8+ T cells in untreated MM was more pronounced in clinical stage III patients than in stage I and II patients. The most pronounced changes were noted in treated MM patients. The significance of the altered T cell subsets in monoclonal gammopathies with regard to polyclonal and tumor B cell regulation remains to be established.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214842     DOI: 10.1111/j.1600-0609.1982.tb00563.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  16 in total

1.  Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut.

Authors:  Kyoung-Mu Lee; Dalsu Baris; Yawei Zhang; H Dean Hosgood; Idan Menashe; Meredith Yeager; Shelia Hoar Zahm; Sophia S Wang; Mark P Purdue; Stephen Chanock; Tongzhang Zheng; Nathaniel Rothman; Qing Lan
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 2.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

3.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

4.  Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease.

Authors:  F Lauria; R Foa; M Cavo; M Gobbi; D Raspadori; M C Giubellino; P L Tazzari; S Tura
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

5.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

6.  T-cell subsets in multiple myeloma. Impact of cytostatic treatment.

Authors:  A Wahlin; G Roos; J Holm
Journal:  Blut       Date:  1985-10

7.  Effect of chemotherapy on T-lymphocyte subsets in B-cell proliferative disorders.

Authors:  C A Emmendörffer; W J Pichler
Journal:  Blut       Date:  1985-03

8.  Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseases.

Authors:  G De Rossi; G De Sanctis; V Bottari; M Tribalto; M Lopez; M T Petrucci; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Production of interleukin 2 in multiple myeloma.

Authors:  T Commes; B Klein; M Jourdan; R Bataille
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

10.  Imbalances of T-cell subsets in monoclonal gammopathies.

Authors:  L Bergmann; P S Mitrou; K C Weber; W Kelker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.